Open Access
ARTICLE
Clinical Significance of CA-199 and LINC01197 in Pancreatic Cancer
Dan Zhang1, Shengyong Fu2,*, Jie Xu3, Xia Sun1
1 Department of Endocrinology, Lishui Municipal Central Hospital, Lishui, China
2 Department of Comprehensive Laboratory, Lishui International Travel Healthcare Center, Lishui, China
3 Department of Anorectal, Lishui Municipal Central Hospital, Lishui, China
* Corresponding Author: Shengyong Fu. Email:
Oncologie 2020, 22(2), 95-105. https://doi.org/10.32604/oncologie.2020.012439
Abstract
This study aimed to explore the expression and clinical significance of
LINC01197 in the serum of patients with pancreatic cancer (PC).
Methods: A
total of 50 PC patients (patient group) treated in our hospital from March 2012 to
April 2014 were collected, and another 50 healthy people (normal group) were
collected for physical examination. The expression of LINC01197 in the serum of
the two groups was detected by qRT-PCR method, and the expression of CA-199
in serum was detected by Roche automatic biochemistry. The expression and
diagnostic values of CA-199 and LINC01197 in PC were analyzed, and the
relationship between LINC01197 and the prognosis of PC patients was observed.
Results: The expression of CA-199 in the patient group was significantly higher
than in the normal group (
p < 0.001). The area under the curve was 0.791 and
0.944, respectively. The incidence rate of Phases III + IV, lymphatic invasion, and
distant metastasis in patients with low expression of LINC01197 is significantly
higher than that in patients with high expression and has higher diagnostic value.
With the progress of clinical staging, the expression of TNM gradually decreased
and there were differences between groups (
p < 0.001). Sperman test analysis
found that the decreased TNM staging of LINC01197 gradually increased (r = –
0.816,
p < 0.001), and the area under the curve of LINC01197 distinguishing phase
I and phase II + phase III + phase IV was 0.930. The 1-year survival rate and 5-
year survival rate of patients in low expression group are lower than those in the
high expression group (P1 year = 0.037, P5 year = 0.014). Distant metastasis is an
independent prognostic factor for PC patients to survive for 1 to 5 years.
Differentiation, TNM staging, and LINC01197 are independent prognostic factors
for PC patients to survive for 5 years.
Conclusion: The low expression of
LINC01197 in PC patients indicates poor prognosis of patients and is expected to
be a potential diagnostic and prognostic indicator of PC.
Keywords
Cite This Article
Zhang, D., Fu, S., Xu, J., Sun, X. (2020). Clinical Significance of CA-199 and LINC01197 in Pancreatic Cancer.
Oncologie, 22(2), 95–105.
Citations